HDG - thanks. Can you please elaborate on the "regulatory exclusivity" definition? Does it mean that only one company (i.e., Amarin) can sell pure EPA drug legally in the EU market? Or it's the exclusivity of the drug itself, i.e., pure EPA for the RIT indications regardless of which brand?
I am not convinced that patents will be enough to protect Amarin in OUS IF this appeal is a loss for Amarin.
Market Data 
Markets 
AI
